Compare Stocks: ETNB, PTGX, PRAX, and KYMR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ETNB 89BIO	$14.84	$14.82	$6.55 ▼ $15.06	$2.20B	1.27	3.57 million shs	55.65 million shs
KYMR Kymera Therapeutics	$105.48 +1.0%	$99.82	$36.65 ▼ $130.05	$8.68B	1.95	740,979 shs	586,219 shs
PRAX Praxis Precision Medicines	$319.23 +3.0%	$304.18	$37.19 ▼ $366.52	$8.90B	2.78	469,650 shs	274,815 shs
PTGX Protagonist Therapeutics	$137.32 +1.1%	$121.76	$50.49 ▼ $143.29	$8.83B	1.78	742,074 shs	430,510 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ETNB 89BIO	0.00%	0.00%	0.00%	0.00%	+58.89%
KYMR Kymera Therapeutics	+4.07%	-1.67%	-8.03%	+21.02%	+139.10%
PRAX Praxis Precision Medicines	+1.49%	+4.82%	-2.65%	-8.28%	+506.91%
PTGX Protagonist Therapeutics	+2.67%	-0.75%	+3.18%	+30.62%	+152.29%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ETNB 89BIO	$14.84	$14.82	$6.55 ▼ $15.06	$2.20B	1.27	3.57 million shs	55.65 million shs
KYMR Kymera Therapeutics	$105.48 +1.0%	$99.82	$36.65 ▼ $130.05	$8.68B	1.95	740,979 shs	586,219 shs
PRAX Praxis Precision Medicines	$319.23 +3.0%	$304.18	$37.19 ▼ $366.52	$8.90B	2.78	469,650 shs	274,815 shs
PTGX Protagonist Therapeutics	$137.32 +1.1%	$121.76	$50.49 ▼ $143.29	$8.83B	1.78	742,074 shs	430,510 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ETNB 89BIO	0.00%	0.00%	0.00%	0.00%	+58.89%
KYMR Kymera Therapeutics	+4.07%	-1.67%	-8.03%	+21.02%	+139.10%
PRAX Praxis Precision Medicines	+1.49%	+4.82%	-2.65%	-8.28%	+506.91%
PTGX Protagonist Therapeutics	+2.67%	-0.75%	+3.18%	+30.62%	+152.29%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ETNB 89BIO	2.00	Hold	$18.17	22.42% Upside
KYMR Kymera Therapeutics	2.83	Moderate Buy	$124.48	18.01% Upside
PRAX Praxis Precision Medicines	2.95	Moderate Buy	$563.50	76.52% Upside
PTGX Protagonist Therapeutics	2.94	Moderate Buy	$123.00	-10.43% Downside

Current Analyst Ratings Breakdown

Latest ETNB, PTGX, PRAX, and KYMR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/5/2026	KYMR Kymera Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
7/30/2026	KYMR Kymera Therapeutics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold	$120.00
7/29/2026	PRAX Praxis Precision Medicines	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$810.00
7/28/2026	KYMR Kymera Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$125.00 ➝ $135.00
7/17/2026	KYMR Kymera Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	PTGX Protagonist Therapeutics	Johnson Rice Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$165.00
7/17/2026	PTGX Protagonist Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
7/16/2026	KYMR Kymera Therapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$120.00 ➝ $140.00
7/14/2026	PTGX Protagonist Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$119.00 ➝ $151.00
7/13/2026	PRAX Praxis Precision Medicines	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
7/13/2026	KYMR Kymera Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform	$106.00 ➝ $115.00

(Data available from 8/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ETNB 89BIO	N/A	N/A	N/A	N/A	$3.34 per share	N/A
KYMR Kymera Therapeutics	$39.21M	221.29	N/A	N/A	$19.42 per share	5.43
PRAX Praxis Precision Medicines	$8.55M	1,040.95	N/A	N/A	$34.85 per share	9.16
PTGX Protagonist Therapeutics	$46.02M	191.90	N/A	N/A	$9.83 per share	13.97

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ETNB 89BIO	-$367.08M	-$3.61	N/A	N/A	N/A	N/A	-94.48%	-80.92%	N/A
KYMR Kymera Therapeutics	-$311.35M	-$3.57	N/A	N/A	N/A	-611.94%	-24.71%	-22.05%	8/5/2026 (Estimated)
PRAX Praxis Precision Medicines	-$303.27M	-$13.37	N/A	N/A	N/A	N/A	-43.02%	-40.22%	8/6/2026 (Estimated)
PTGX Protagonist Therapeutics	-$130.15M	-$1.81	N/A	N/A	N/A	-154.88%	-17.76%	-16.47%	8/5/2026 (Estimated)

Latest ETNB, PTGX, PRAX, and KYMR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	PRAX Praxis Precision Medicines	-$3.67	N/A	N/A	N/A	$1.25 million	N/A
8/5/2026	Q2 2026	KYMR Kymera Therapeutics	-$0.7126	-$0.62	+$0.0926	-$0.62	$32.78 million	$65.00 million
8/5/2026	Q2 2026	PTGX Protagonist Therapeutics	$2.23	$2.29	+$0.06	$2.29	$199.81 million	$213.48 million
5/7/2026	Q1 2026	PRAX Praxis Precision Medicines	-$3.58	-$3.20	+$0.38	-$3.20	$0.10 million	N/A
5/5/2026	Q1 2026	PTGX Protagonist Therapeutics	-$0.5004	$0.05	+$0.5504	$0.05	$11.70 million	$56.37 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ETNB 89BIO	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A
PTGX Protagonist Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ETNB 89BIO	0.07	15.19	15.19
KYMR Kymera Therapeutics	N/A	10.81	10.81
PRAX Praxis Precision Medicines	N/A	15.88	15.88
PTGX Protagonist Therapeutics	N/A	17.76	17.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ETNB 89BIO	N/A
KYMR Kymera Therapeutics	N/A
PRAX Praxis Precision Medicines	67.84%
PTGX Protagonist Therapeutics	98.63%

Insider Ownership

Company	Insider Ownership
ETNB 89BIO	2.60%
KYMR Kymera Therapeutics	15.98%
PRAX Praxis Precision Medicines	3.00%
PTGX Protagonist Therapeutics	5.19%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ETNB 89BIO	40	148.31 million	144.45 million	Optionable
KYMR Kymera Therapeutics	170	82.26 million	69.11 million	Optionable
PRAX Praxis Precision Medicines	110	27.88 million	27.04 million	Optionable
PTGX Protagonist Therapeutics	120	64.31 million	60.97 million	Optionable

ETNB, PTGX, PRAX, and KYMR Headlines

Recent News About These Companies

Protagonist Reports Second Quarter 2026 Financial Results and Provides Corporate Update

2 hours ago | accessnewswire.comA

PTGX’s PN-881 Phase 1 Completion: A Quiet Milestone With Big Pipeline Implications

August 5 at 12:31 PM | tipranks.com

Protagonist Therapeutics Reports Granting of Inducement Awards

August 4 at 4:05 PM | accessnewswire.comA

The Manufacturers Life Insurance Company Purchases 14,478 Shares of Protagonist Therapeutics, Inc. $PTGX

August 3 at 5:11 AM | marketbeat.com

Perceptive Advisors LLC Sells 119,546 Shares of Protagonist Therapeutics, Inc. $PTGX

August 2 at 6:07 AM | marketbeat.com

Sei Investments Co. Buys 45,851 Shares of Protagonist Therapeutics, Inc. $PTGX

August 2 at 4:55 AM | marketbeat.com

Dimensional Fund Advisors LP Has $53.54 Million Holdings in Protagonist Therapeutics, Inc. $PTGX

August 2 at 3:36 AM | marketbeat.com

Segall Bryant & Hamill LLC Acquires 83,654 Shares of Protagonist Therapeutics, Inc. $PTGX

August 1, 2026 | marketbeat.com

First Trust Advisors LP Buys 41,404 Shares of Protagonist Therapeutics, Inc. $PTGX

August 1, 2026 | marketbeat.com

Janus Henderson Group PLC Acquires 241,546 Shares of Protagonist Therapeutics, Inc. $PTGX

July 31, 2026 | marketbeat.com

Protagonist Therapeutics, Inc. $PTGX Shares Acquired by Stempoint Capital LP

July 30, 2026 | marketbeat.com

Protagonist Therapeutics (PTGX) Projected to Post Earnings on Wednesday

July 29, 2026 | marketbeat.com

ADAR1 Capital Management LLC Lowers Stock Holdings in Protagonist Therapeutics, Inc. $PTGX

July 29, 2026 | marketbeat.com

Rubric Capital Management LP Takes Position in Protagonist Therapeutics, Inc. $PTGX

July 28, 2026 | marketbeat.com

Weiss Asset Management LP Takes $1.03 Million Position in Protagonist Therapeutics, Inc. $PTGX

July 28, 2026 | marketbeat.com

Protagonist Therapeutics, Inc. $PTGX Stock Position Lifted by Eagle Health Investments LP

July 28, 2026 | marketbeat.com

Protagonist Therapeutics, Inc. $PTGX Shares Acquired by Orbimed Advisors LLC

July 27, 2026 | marketbeat.com

Granahan Investment Management LLC Purchases Shares of 27,391 Protagonist Therapeutics, Inc. $PTGX

July 26, 2026 | marketbeat.com

Protagonist Therapeutics, Inc. $PTGX Stock Position Decreased by Bank of New York Mellon Corp

July 26, 2026 | marketbeat.com

Fifth Third Bancorp Increases Stock Holdings in Protagonist Therapeutics, Inc. $PTGX

July 25, 2026 | marketbeat.com

Allspring Global Investments Holdings LLC Increases Stock Position in Protagonist Therapeutics, Inc. $PTGX

July 25, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ETNB, PTGX, PRAX, and KYMR Company Descriptions

89BIO NASDAQ:ETNB

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

Kymera Therapeutics NASDAQ:KYMR

$105.48 +1.09 (+1.04%)

Closing price 04:00 PM Eastern

Extended Trading

$111.08 +5.60 (+5.31%)

As of 06:08 PM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Praxis Precision Medicines NASDAQ:PRAX

$319.23 +9.16 (+2.95%)

Closing price 04:00 PM Eastern

Extended Trading

$322.24 +3.01 (+0.94%)

As of 06:23 PM Eastern

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Protagonist Therapeutics NASDAQ:PTGX

$137.32 +1.51 (+1.11%)

Closing price 04:00 PM Eastern

Extended Trading

$138.96 +1.64 (+1.19%)

As of 06:12 PM Eastern

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ETNB, PTGX, PRAX, and KYMR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ETNB, PTGX, PRAX, and KYMR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ETNB, PTGX, PRAX, and KYMR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ETNB, PTGX, PRAX, and KYMR Company Descriptions

89BIO NASDAQ:ETNB

Kymera Therapeutics NASDAQ:KYMR

Praxis Precision Medicines NASDAQ:PRAX

Protagonist Therapeutics NASDAQ:PTGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ETNB, PTGX, PRAX, and KYMR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ETNB, PTGX, PRAX, and KYMR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ETNB, PTGX, PRAX, and KYMR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ETNB, PTGX, PRAX, and KYMR Company Descriptions

89BIO NASDAQ:ETNB

Kymera Therapeutics NASDAQ:KYMR

Praxis Precision Medicines NASDAQ:PRAX

Protagonist Therapeutics NASDAQ:PTGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools